The estimated Net Worth of Peter Fernandes is at least $535 Tysiąc dollars as of 9 December 2022. Mr. Fernandes owns over 32,500 units of Bellerophon Therapeutics Inc stock worth over $1,300 and over the last 10 years he sold BLPH stock worth over $0. In addition, he makes $533,977 as Chief Regulatory and Safety Officer at Bellerophon Therapeutics Inc.
Peter has made over 1 trades of the Bellerophon Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 32,500 units of BLPH stock worth $1,300 on 9 December 2022.
The largest trade he's ever made was exercising 32,500 units of Bellerophon Therapeutics Inc stock on 9 December 2022 worth over $1,300. On average, Peter trades about 1,806 units every 0 days since 2015. As of 9 December 2022 he still owns at least 32,500 units of Bellerophon Therapeutics Inc stock.
You can see the complete history of Mr. Fernandes stock trades at the bottom of the page.
Peter Fernandes serves as Chief Regulatory and Safety Officer of the Company. Mr. Fernandes was Vice President of Global Regulatory Affairs at Ikaria Inc., from October 2012 to May 2015, and in this capacity also led our regulatory group since its inception in February of 2014. Previously, he led Regulatory Affairs and Quality Assurance for OptiNose, Inc. from October 2010 to September 2012, was Vice President US Drug Regulatory Affairs Respiratory and US DRA Respiratory Franchise Head for Novartis Pharmaceuticals from November 2007 to October 2010. He has also served as the Head of US Development Site and Vice President of Regulatory Affairs and Quality Assurance at Altana Pharma, a subsidiary of Nycomed Inc., and led the US Respiratory and GI Drug Regulatory Affairs group at Boehringer Ingelheim. Mr. Fernandes has an M. Pharm. from the Grant Medical College and a B. Pharm. from the K.M. K. College of Pharmacy, both at the University of Bombay in India.
As the Chief Regulatory and Safety Officer of Bellerophon Therapeutics Inc, the total compensation of Peter Fernandes at Bellerophon Therapeutics Inc is $533,977. There are 1 executives at Bellerophon Therapeutics Inc getting paid more, with Fabian Tenenbaum having the highest compensation of $1,400,000.
Peter Fernandes is 65, he's been the Chief Regulatory and Safety Officer of Bellerophon Therapeutics Inc since 2015. There are 1 older and 15 younger executives at Bellerophon Therapeutics Inc. The oldest executive at Bellerophon Therapeutics Inc is Peter Fernandes M. Pharm, 66, who is the Interim Principal Exec. Officer, Chief Regulatory & Safety Officer.
Peter's mailing address filed with the SEC is 20 INDEPENDENCE BLVD., SUITE 402, WARREN, NJ, 07059.
Over the last 10 years, insiders at Bellerophon Therapeutics Inc have traded over $8,853,497 worth of Bellerophon Therapeutics Inc stock and bought 9,412,012 units worth $57,370,250 . The most active insiders traders include Robert Nelsen, Adam Weinstein oraz Associates Iv L P Venrock H.... On average, Bellerophon Therapeutics Inc executives and independent directors trade stock every 61 days with the average trade being worth of $10,679. The most recent stock trade was executed by Capital Management Lp Puiss... on 13 October 2023, trading 1,076,841 units of BLPH stock currently worth $107,684.
bellerophon therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
Bellerophon Therapeutics Inc executives and other stock owners filed with the SEC include: